SCHEMBL6782285

SCHEMBL6782285

Cc1cccc(C(N)CC(=O)OC(C)(C)C)n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 2/20 0.39
P2RX7 Q99572 1/20 0.38
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35
SLC7A5 Q01650 1/20 0.35
GRM5 P41594 1/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
RAB9A P51151 1/20 0.33
MEN1 O00255 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
TGM2 P21980 1/20 0.32
TGFBR1 P36897 1/20 0.32
NOS3 P29474 1/20 0.32
NOS2 P35228 1/20 0.32
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27485171 0.79 IRAK4 (0.54) IRAK4P2RX7HTTRECQLGRM5
SCHEMBL19410196 0.79 CYP2C19 (0.42) KMT2AALDH1A1KDM4ERAB9AMEN1
SCHEMBL30915255 0.79 CYP2C19 (0.42) KMT2AALDH1A1KDM4ERAB9AMEN1
SCHEMBL6070621 0.78 ALDH1A1 (0.42) HTTKMT2AALDH1A1KDM4ERAB9A
SCHEMBL15630765 0.77 SLC7A5 (0.38) SLC7A5KMT2A
SCHEMBL469053 0.73 CTSS (0.42) SLC7A5KMT2AALDH1A1
SCHEMBL1573827 0.73 CTSS (0.42) SLC7A5KMT2AALDH1A1
SCHEMBL1952090 0.73 CTSS (0.42) SLC7A5KMT2AALDH1A1
SCHEMBL6779226 0.73 KMT2A (0.34) HTTRECQLGRM5KMT2AALDH1A1
SCHEMBL7837944 0.72 ALDH1A1 (0.34) HTTSLC7A5KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed